Rita Kalsyan: ICP, Greater Noida, India.Anil K Sahdev and Vinit Raj:Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Vidya Vihar, Raebareli Road, Lucknow 226025, India.

As we aware that Atorvastatin is BCS (Class II) drug and has poor solubility, extreme first pass metabolism and thus has poor bioavailability; on keeping in mind of all that factors we have to select that route which minimize all these effects and such formulation which deliver the drug to brain as much as possible. Hence we select intranasal route it offers direct access of drug to brain through olfactory route and avoid first pass metabolism and is suitable to deliver drugs via nanoformulation and have previously been utilized for enhanced brain delivery. NLC formulation could be able to deliver atorvastatin conveniently by intranasal route. NLC are nano sized delivery systems used to deliver drugs via intranasal route in different disease conditions. Their utility in intranasal route has been well documented. They can be suitably modified for improved retention and can cross mucosal barrier.